期刊文献+

唑来膦酸注射液治疗骨转移疼痛近期疗效分析 被引量:3

下载PDF
导出
摘要 目的观察第三代双膦酸盐类唑来膦酸治疗骨转移疼痛的近期疗效。方法对2004年1~2007年10月我院76例癌症晚期骨转移患者给予唑来膦酸治疗,其中男47例,女29例,单发骨转移灶8例,多发骨转移灶68例,合并高钙血症5例。结果止痛有效率76.32%,单发骨转移灶有效率87.5%,多发骨转移灶有效率75%,5例高血钙均降至正常,无重要器官的毒副作用。结论唑来膦酸是治疗骨转移疼痛的有效药物,且可治疗高钙血症及维持血钙正常水平。
作者 王蕊 冯春美
出处 《中国现代医生》 2009年第15期204-204,214,共2页 China Modern Doctor
  • 相关文献

参考文献8

  • 1张天泽 徐光炜.肿瘤学[M].天津:天津科学技术出版社,1996.1209.
  • 2Coloman R. Clinical aspects of metastasis bone disease. In:Coloman R, Rubens RD, eds , metastasis bone disease[J]. Camforth : The Parthenon Publishing Group Lid, 1992:11.
  • 3Major P,Lortholary A,Hon J,et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy:a pooled analysis of two randomized ,controlled clinical trials[J]. J Clin Oncol, 2001, 19:558-567.
  • 4Eydokiou A, Labrinidis A. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis[J]. Bone, 2003,33 (2) : 216-228.
  • 5Neville-Webbe H, Coleman RE. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J]. Palliat Med, 2003,17(6):539-553.
  • 6孙辉,周均田,张燕军,陈振东,王秀问,刘基巍.注射用唑来膦酸治疗恶性肿瘤引起的溶骨性骨转移疼痛临床研究报告[J].中国肿瘤临床,2005,32(15):885-888. 被引量:15
  • 7赵翌,李颖,白松,高亚杰,刘基巍.唑来膦酸治疗癌症骨转移疼痛临床观察[J].癌症进展,2005,3(4):395-398. 被引量:13
  • 8郑荣生,秦凤展,陈振东,熊福星.唑来膦酸注射液治疗恶性肿瘤骨转移疼痛50例[J].中国新药杂志,2005,14(2):214-216. 被引量:5

二级参考文献27

  • 1李淑芬,佟仲生,汪旭,何丽宏.博宁及博宁联合化疗治疗骨转移引起疼痛的临床观察[J].中国肿瘤临床,2004,31(21):1250-1252. 被引量:6
  • 2[4]Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-bingding proteins, including Ras J Bone Miner Res, 1998, 13:581
  • 3[5]Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular molecular mechanisms of action of bisphophonates. Cancer,2000, 88 (Suppl) : 2961
  • 4[6]Benford HL, Helfrich MH, Sebti S, et al. Inhibition of protein geranylation by bisphosphonates and GGTI298 causes activation of caspase-3 like proteases in osteoclasts. Calcif Tissue Int, 1999,64 (Suppl) :45
  • 5[7]Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 429446, a new, potent, heterocyclinc bisphosphonate compound. J Bone Miner Res, 1994, 9:745
  • 6[8]Body JJ, Lortholary A, romieu G, et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res, 1999, 14:1557
  • 7[9]Rosen L, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase Ⅲ, doubleblind, randomized trial. The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol, 2003, 21:3150
  • 8[10]Saad F, Gleason DM, Muray R, et al. A randomized, placebo-controled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst,2002, 94:1458
  • 9[11]Rosen L, Gordon D, Tchekmedyian S, et al. zoledronic acid significantly reduce skeletal-related events (SREss) in patients with bone metastases from solid tumors. Proc Am Soc Clin Oncol, 2002, 21:295A
  • 10[12]Rosen L, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer of osteolytic lessons of multiple myeloma: A phaseⅢ, double-blind, comparative trial. Cancer,2001, 7:377

共引文献571

同被引文献21

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部